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The current environment
The following are some thoughts that I would like to share on 
the sustainability of personalised medicine. I present my per­
sonal view because unfortunately there have been very few 
studies on this topic. 
To achieve sustainability, there is a very basic equation that 
says that income has to be equal to or greater than expenditure. 
The same applies for a good or commodity in question, so that,
Income ≥ Expenditure (eq. 1)
Income ≥ Price × Quantity (eq. 2)
 
If we look at the cost of sequencing a complete genome, we 
see that it is steadily decreasing. According to Moore’s Law, 
which describes the trend of a computer processor doubling in 
complexity, generally translating into greater practical comput­
ing performance every two years accompanied by a decrease 
in cost, then sequencing costs (which depend to a great extent 
on computer hardware, computational tools, and other tech­
nological developments) should likewise progressively become 
much lower (Fig.1) [4]. The Google­launched initiative 
23andMe, Inc., for example, has reduced the cost of sequenc­
ing an entire human genome from US$299 in 2012, to just 
US$99 in 2013. Thus, with regard to equation 2, price is no 
longer the limiting factor; instead, it will soon be quantity.
According to the OECD, while health spending grew, on aver­
age, close to 5 % from 2000 to 2009, expenditures in healthcare 
fell sharply in 2010 and remained flat in OECD countries in 2011 
as the economic crisis continued to have a particularly strong 
impact in those European counties hardest hit by it (Fig. 2). But if 
we look at the standardised units of parity purchasing power, 
standardised to US$ to facilitate international comparisons, we 
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see that healthcare expenditures have actually increased in re­
cent years (Fig. 3). In other words, despite the financial crisis, 
consumption of healthcare resources is growing. If this has a real 
impact on resource availability, then the only way to achieve 
equilibrium is for expenditures on new resources to be balanced 
by future gains. But can personalised medicine meet this need?
Income ≥ Price × (increased cost of new technology 
– future savings) (eq. 3)
Market size forecast: the supply side
If we look at the supply side and try to assess the size of the mar­
ket, it becomes immediately clear that the numbers for the core 
of P4 medicine (personalised, preventive, predictive, and partici­
patory medicine), i.e., personalised medical care, nutrition and 
wellness, are very, very large. Moreover, the 2015 predictions for 
this market are even larger (Fig. 4). The figure for the market size 
in 2012 is approximately U$208 billion [7]. But we have to con­
Fig. 1. Cost of sequencing a human­sized genome 
and hypothetical data reflecting Moore’s Law. The 
costs include: labour, sequencing equipment, IT ac­
tivities related to sequence production, shotgun library 
construction, and indirect costs. There is a profound 
outpace of Moore’s Law in 2008 when sequencing 
centres transitioned to ‘second­/next­generation’ 
DNA sequencing technologies. Source: National Hu­
man Genome Research Institute [4].
Fig. 3. Average annual growth in health spending across 
OECD countries in real terms, 2000–2011. Source: OECD 
Health Data 2013, [5].
Fig. 2. Average OECD health expenditure growth rates in 
real terms, 2000–2011, public and total. Source: OECD 
Health Data 2013 [5].
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sider that much of this sum includes mergers and acquisitions, 
infrastructure construction for personalised medicine (new labs, 
and the hiring of skilled staff), with a far smaller amount devoted 
to drug costs and direct healthcare provision.  
Pharmacogenetics and public expenditure on 
drugs
A look at the phamacogenetics aspect of personalised medi­
cine, the equivalent of its Holy Grail, quickly shows that: (i) there 
are many diseases for which a particular drug is ineffective (Ta­
ble 1) and (ii) there are many diseases that have a genetic com­
ponent, reflecting genetic mutations that may be targetable by 
specific drugs. These observations provide the scientific ration­
ale underlying the claim that personalised medicine can lower 
drug costs. But we should also consider how drug prices are 
set: the smaller the target population, the higher the price. 
Imagine a newly developed drug that will cure twice as 
many people or will cure the same number of people but only 
half of the population must be treated. There is no doubt that 
the price of that drug will be twice the current standard. Ac­
cordingly, there is little reason to think that personalised med­
icine will reduce healthcare costs by reducing drug costs. In 
this sense, we can learn a lot from the market for orphan 
drugs, i.e., drugs developed specifically to treat rare medical 
conditions (orphan diseases). The orphan drug market shares 
several features with personalised medicine. Moreover, sub­
stitution is not possible. In some diseases, treating a subpop­
ulation responsive to the drug does not mean that other pop­
ulations will not be treated, nor does it mean that whenever 
this drug fails—because it will still fail—other drugs will not be 
used, such that, ultimately, the drug armamentarium for cer­
tain diseases will expand. Finally, there is the J­curve effect 
on drug substitution, in which relatively efficient drugs are 
withdrawn to incorporate more effective (though less efficient) 
ones, but since price is supposed to be proportional to vol­
ume, the overall drug costs increase. 
In Spain, the healthcare drug bill has decreased since 2003, 
reflecting the targeting of drug prices. However, the prescription 
trend has remained unchanged or is even slightly higher than 
before. Thus, by replacing cheaper drugs for more expensive 
ones, the impact will be even greater. A good example of this is 
Trastuzumab, a drug that targets breast cancer with a particular 
genetic biomarker. But while the incidence of breast cancer has 
decreased over the last decade, the use of Trastuzumab has 
increased. Why this is so merits investigation. 
As the European Science Foundation has stated, “[a] realistic 
expectation could thus be cost containment rather than reduc­
tion, along with improved public health and quality of life. In other 
words, personalised medicine might be reasonably expected to 
generate a more efficient, rational use of resources. A more real­
istic promise is thus an improved return on investment.” [2]
Another important consideration on the supply side is mar­
ket segmentation. Again, comparison with the orphan dis­
Fig. 4. Personalised medicine market 
size, 2009 and 2015. Source: Pricewa­
terhouseCoopers analysis [7]. 
Table 1. Average percentage of the patient population for 
which a particular drug is ineffective
Disease Patient population for which 
a particular drug is 
ineffective (%)
Anti­depressants (SSRIs) 38 
Asthma 40 
Diabetes 43 
Arthritis 50 
Alzheimer’s 70 
Cancer 75 
Source of data: [4].
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ease market is appropriate [6]. In the view of some pharma­
ceutical companies, the identification of a gene that 
determines some features of a disease defines a separate 
disease with very low incidence, which accordingly should 
benefit from the privileges granted orphan drugs. This strate­
gy has been around for a few years, but its practice should be 
scrutinised. For example, atrial fibrillation is the most common 
cardiac arrhythmia. If, based on genetic findings, it were to 
qualify as an orphan disease, the impact on healthcare costs 
would be enormous. The same is true for chronic pulmonary 
disease, and the combined impact of these two diseases on 
healthcare costs would be insurmountable.
Market expectations and value
From the business side, the pharmaceutical industry has a 
huge stake in genetic diseases, but its business model is not 
affected by supply and demand. Take the example of Roche, 
which a few years ago sought to buy the genetic diagnostics 
firm Illumina. In 2010, the share price of Illumina had fallen 
significantly, but as rumours of the purchase circulated, the 
share value increased steeply and then continued to fluctu­
ate. Meanwhile, the value of Roche’s shares remained stable. 
While the investment was likely to be quite profitable, the 
gene diagnostics industry is very unstable. Indeed, in 2012, 
the value of genetics or genetics­based companies was ei­
ther stable or decreased slightly. For the major players in the 
pharmaceutical industry, the value of the genetics market is 
not clear, but it is innovation­based and therefore potentially 
highly profitable down the road.
It is highly likely that most biotechnology companies will fail 
in the very short run, so their business model is largely based 
on rapid growth followed by the sale of the company. This de­
mands that the company generates high short­term profits to 
guarantee its eventual sale. The figures for failure in the bio­
technology business are illustrative: if failure is defined as liqui­
dating all assets, with investors losing most or all of the money 
they invested in the company, then the failure rate for start­ups 
is 30–40 %; if failure is defined as the failure to see a return on 
investment, then the failure rate is 70–80 %; if failure is defined 
as the failure to meet projections, then the failure rate is a 
spectacular 90–95 %. The biotechnology bubble is expanding 
very fast, supported by enormous sums of money, but its 
burst seems inevitable. 
Creating value: the demand side
On the demand side are the buyers, which basically means 
the various countries, as purchasers of healthcare products. 
As they say, beauty is in the eye of the beholder, and this is 
true for value as well. Value is subjective and related to indi­
vidual willingness to pay a price that is more than the cost of 
production. Value is related to several factors: novelty, appro­
priateness, competitive advantage, dynamic capabilities, or­
ganizational knowledge, etc. Furthermore, buyers must have 
the knowledge to recognise the value of the object of interest. 
In the case of genetics­based and personalised medicine, the 
buyer has to be trained in its evaluation, despite the many 
uncertainties regarding the therapeutic impact on disease. 
Because basically buyers do not purchase genes, they pur­
chase diseases and their treatment.  
However, the major issue is that personalised medicine is, as 
defined by Pricewaterhouse Coopers, “a holistic, individual 
model of care that examines each individual’s unique makeup 
and designs appropriate strategies for maintaining wellness and 
treating illness. ” In most developed countries, we have been 
successful at building health systems that are not individual, but 
rather that are based on risk sharing. Individualised medicine 
goes against that idea, moving from the fundamental goal of 
population­based, public benefit to non­risk­sharing among in­
dividuals. This is an important consideration because there will 
be obvious consequences in the attempts to bridge this gap. 
The main concerns of regulatory agencies such as the US 
Food and Drug Administration (FDA) and the European Medi­
cines Agency (EMA), are efficacy, quality, and safety, whereas 
those of purchasers, on the demand side, are related to a 
drug’s efficacy, e.g., whether an appropriate adjustment on 
the supply side is needed to meet the health needs of citi­
zens, or whether a comprehensive or reasonable range of 
Fig. 5. Danseuse espagnole I (Spanish dancer I, 1928), by Joan Miró 
(Barcelona, Spain, 1893–Palma de Mallorca, Spain, 1983). Source: 
Reina Sofía National Art Museum, Madrid [http://www.museoreinaso­
fia.es/en/collection/artwork/danseuse­espagnole­i­spanish­dancer­i].
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services should be offered. Consider the painting by Joan 
Miró shown in Fig. 5. It is the minimal expression of a dancer, 
and a good reminder of the aim of public health: the minimum 
amount of healthcare provision that will achieve the appropri­
ate level of care while taking into account opportunity cost, 
equity, and combinations thereof. 
The health policy implications
Understanding the macroscopic (ethical, legal, and social) im­
plications of genomic medicine requires an analysis of the ways 
in which genetic information and genetic approaches to dis­
ease affect people individually, both within their families and 
communities and in their social and working lives. Genomic 
medicine presents particular challenges to clinicians regarding 
their ethical and professional responsibilities [1]. At the micro­
scopic level there are pharmacogenetics and pharmacoge­
nomics implications, since patients vary in their drug respon­
siveness. Within a tumour, for example, some drug­targetable 
genes might be expressed and others not.
It is too soon to evaluate the link between personalised 
medicine and its impact on the population. In the word of Io­
annidis, “[…] the ambitious enterprise of personalised medi­
cine has to meet many challenges: a torrent of information 
with poor research and reporting standards, and a poor repli­
cation record; intrinsic difficulties in the predictive modelling; 
a lack of systematization; subtle effects of small magnitude; a 
disconnect between the science and its understanding by 
health practitioners and the general public; uncertainty even 
in the types of outcomes that we want to employ this informa­
tion for, if at all; and even risks of causing more harm than 
good in some circumstances.” [3]
 
So we return to the basic equation,
income ≥ price * ( ∑ diagnostic + prevention 
+ treatment use) (eq. 4)
Should diagnosis, prevention, and treatment compensate 
for the expected increased costs? Whenever new diagnostic 
tools and treatments enter the market, there is an increase in 
the target population as new cases are detected, which im­
plies higher diagnostic costs. Furthermore, in this newly dis­
criminated population, we can ask: What is the cost of the 
new treatment? What is the cost of the side effects? What is 
the cost of the use of healthcare resources? The new diagnos­
tic tools must also be incorporated into the payment system, 
as specified by the Diagnostic Related Group. Table 2 shows 
the comparative costs of different procedures related to colo­
rectal cancer for Spain. The cost KRAS determination is a fifth 
of that of total colectomy. How can we incorporate the cost of 
that genetic test into our current system? In terms of diagnosis 
and prediction, if the genetic risk of every 20­year old in Spain 
(455,824 people as of October 2012) is determined, at US$99 
per test [9], this comes to a total of approximately 40 million 
Euros per year. This is an unsustainable figure by itself, and 
does not even take into account the consequences of a posi­
tive test. Moreover, there are issues related to insurance, reim­
bursement, and population segmentation.
How to adapt?
Current European Health Policy is based on redistribution. Per­
sonalised medicine may impose future difficulties in ensuring 
equity. For individuals at high risk, moral hazard tells us that 
they will overuse the system, whereas individuals at low risk will 
choose to opt out of the system, to avoid paying for the risk of 
others. This is a real threat to Bismarckian models (used in Ger­
many, France, Belgium, and the Netherlands), in which the 
health insurance system is financed jointly by employers and 
employees through payroll deductions such that everyone is 
covered and profit­making is forbidden, and doctors and hos­
pitals tend to be private. In this case, there would be a need to 
further redistribute risks. There would also be profound finan­
cial, legal, and ethical implications in: the use of genetics infor­
mation, insurance de­linked to genetic testing, controlling the 
shift from private to public because of high risks/costs, profit­
making, higher transaction costs incurred by private insurance 
to check risks, etc. 
How can prices be controlled? Mostly through risk­sharing 
schemes, although the tools needed to assess outcomes are 
highly complex. The Velcade experience in the UK is an exam­
ple of the very high transaction costs. Also, risk­sharing is not 
efficient without budget limits. It is much cheaper to incorpo­
rate uncertainty in the selling price: paying for performance 
within a disease group, for procedures, for capitation systems 
(should they include some form of redistribution), etc.? With 
the currently available technology, IT systems could be used 
to carry out observational studies and analyse potential phe­
notypic correlations. By gathering information on age, sex, 
place of residence, places visited, and other information that is 
already available, complex IT solutions can be applied to ob­
tain a similar risk profile as that promised by genetic testing. 
Table 2. Comparative cost of different procedures related to 
colorectal cancer diagnostic and treatment in Spain. 
Procedure Cost (€)
Total colonoscopy or ileoscopy, biopsy 210.89 
Rectosigmoidoscopy, biopsy 84.36 
Hemicolectomies by laparotomy 940.80 
Total colectomy 1282.91 
Complicated biopsy 86.38 
Intraoperative biopsy 172.76 
Simple biopsy, macro­ and microscopic study 69.11 
Detection of KRASa 200.00 
aA biomarker for colon cancer. Source of data: Nomenclator, Medical 
Association of Barcelona (COMB) [www.comb.cat].
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This is something that insurance companies are well aware of. 
So rather than engage in something for which there is no link 
between cost and consequence, there may be other sources 
of relevant information.
Conclusions
There is a divide between populations and individuals, there is 
a high level of uncertainty, and there are macroeconomic 
consequences. Does that mean we should not invest in per­
sonalised medicine? No, just that it may be too early to reap 
its benefits. So why invest in uncertainty? First, to reduce un­
certainty. Second, because it means investing in research 
and thus in the technology that comes with it, and that means 
creating wealth while educating society. I believe that we 
should invest even if we do not really know what the result will 
be. But, by investing in a cluster of businesses, not only in 
genetics or personalised medicine, we are investing in an 
ecosystem that may ultimately deliver benefits, and perhaps 
not only to the healthcare system.
 As to whether personalised medicine will be sustainable, 
income will, at best, most likely be neutral in the coming years 
whereas expenditures for diagnostics and prevention will in­
crease and treatment will, at best, have a neutral effect. The 
implementation of personalised medicine requires the conflu­
ence of several sectors: insurance coverage and reimburse­
ment, genetic privacy and legal protection, medical education, 
healthcare information technology, and regulation. The full im­
plementation and standardization of personalised medicine 
can only be achieved when there has been a recognition of 
value, the enactment of policy or legislation, and pilot studies 
and sufficient precedent in all these sectors.
References
1.  Clayton EW (2003) Ethical, Legal, and Social Implications 
of Genomic Medicine. N Engl J Med 349:562­569
2.  European Science Foundation (2012) Personalised Medi­
cine for the European Citizen. Towards a more precise 
medicine for the diagnosis, treatment and prevention of 
disease 
3.  Ioannidis JPA (2009) Limits to forecasting in personalized 
medicine: an overview. International Journal of Forecast­
ing 25:773­783
4.  National Human Genome Research Institute [http://ge­
nome.gov/sequencingcosts]
5.  OECD Health Data 2013 [http://www.oecd.org/health/
healthdata]
6.  Orphanet. The portal for rare diseases and orphan drugs 
[www.orpha.net]
7.  PricewaterhouseCoopers (2009) The New Science of 
Personalised Medicine: Translating the promise into 
practice [http://www.pwc.com/us/en/healthcare/publi­
cations/personalized­medicine.jhtml].
8.  Spear BB, Heath­Chiozzi Margo, Huff J (2001) Clinical 
application of pharmacogenetics. Trends in Molecular 
Medicine 7:201­204
9.  23andMe [www.23andme.com]
